Janux Therapeutics, Inc. (JANX): Price and Financial Metrics

Janux Therapeutics, Inc. (JANX): $9.01

0.41 (-4.35%)

POWR Rating

Component Grades

Momentum

F

Stability

C

Sentiment

Quality

D

Add JANX to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#185 of 347

in industry

JANX Price/Volume Stats

Current price $9.01 52-week high $23.64
Prev. close $9.42 52-week low $5.65
Day low $8.93 Volume 67,100
Day high $9.48 Avg. volume 114,703
50-day MA $8.21 Dividend yield N/A
200-day MA $11.56 Market Cap 415.97M

JANX Stock Price Chart Interactive Chart >

JANX POWR Grades

  • JANX scores best on the Sentiment dimension, with a Sentiment rank ahead of 70.42% of US stocks.
  • JANX's strongest trending metric is Growth; it's been moving up over the last 177 days.
  • JANX's current lowest rank is in the Momentum metric (where it is better than 4.94% of US stocks).

JANX Stock Summary

  • JANUX THERAPEUTICS INC's stock had its IPO on June 11, 2021, making it an older stock than only 6.72% of US equities in our set.
  • With a price/sales ratio of 49.29, JANUX THERAPEUTICS INC has a higher such ratio than 96.69% of stocks in our set.
  • JANX's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of merely 10.28% of US stocks.
  • Stocks that are quantitatively similar to JANX, based on their financial statements, market capitalization, and price volatility, are LYEL, KRON, PLRX, STOK, and PRAX.
  • Visit JANX's SEC page to see the company's official filings. To visit the company's web site, go to www.januxrx.com.

JANX Valuation Summary

  • In comparison to the median Healthcare stock, JANX's EV/EBIT ratio is 153.54% lower, now standing at -6.8.
  • Over the past 30 months, JANX's price/sales ratio has gone down 2465.7.

Below are key valuation metrics over time for JANX.

Stock Date P/S P/B P/E EV/EBIT
JANX 2023-11-20 49.3 1.2 -6.7 -6.8
JANX 2023-11-17 47.3 1.1 -6.4 -6.5
JANX 2023-11-16 48.1 1.2 -6.5 -6.6
JANX 2023-11-15 47.9 1.2 -6.5 -6.6
JANX 2023-11-14 45.4 1.1 -6.1 -6.3
JANX 2023-11-13 38.7 0.9 -5.2 -5.3

JANX Price Target

For more insight on analysts targets of JANX, see our JANX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $35.00 Average Broker Recommendation 1.38 (Strong Buy)

Janux Therapeutics, Inc. (JANX) Company Bio


Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. It is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. The company was incorporated in 2017 and is headquartered in La Jolla, California.


JANX Latest News Stream


Event/Time News Detail
Loading, please wait...

JANX Latest Social Stream


Loading social stream, please wait...

View Full JANX Social Stream

Latest JANX News From Around the Web

Below are the latest news stories about JANUX THERAPEUTICS INC that investors may wish to consider to help them evaluate JANX as an investment opportunity.

Does Janux Therapeutics, Inc. (JANX) Have the Potential to Rally 205.5% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 205.5% in Janux Therapeutics, Inc. (JANX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Yahoo | December 1, 2023

Wall Street Analysts See a 220.17% Upside in Janux Therapeutics, Inc. (JANX): Can the Stock Really Move This High?

The consensus price target hints at a 220.2% upside potential for Janux Therapeutics, Inc. (JANX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Yahoo | November 15, 2023

Janux Therapeutics, Inc. (JANX) Loses -34.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for Janux Therapeutics, Inc. (JANX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Yahoo | November 10, 2023

Janux Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

SAN DIEGO, November 07, 2023--Janux Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

Yahoo | November 7, 2023

We're Not Very Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Yahoo | September 23, 2023

Read More 'JANX' Stories Here

JANX Price Returns

1-mo 36.10%
3-mo -11.54%
6-mo -28.38%
1-year -39.97%
3-year N/A
5-year N/A
YTD -31.59%
2022 -33.25%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!